Description
Advanced Clonazolam 0.5mg | Benzodiazepine Profile & Properties
Clonazolam 0.5mg is a synthetic benzodiazepine derivative also known as clonitrazolam. It belongs to the triazolobenzodiazepine family and is structurally related to other compounds within the benzodiazepine class.
Clonazolam was originally synthesized in the 1970s but was never developed as an approved pharmaceutical medicine. It later became associated with the market for novel psychoactive substances. Compared with established benzodiazepines, substantially less clinical information is available concerning its pharmacology, metabolism, toxicity, and long-term effects.
The chemical structure of Clonazolam 0.5mg includes a triazolobenzodiazepine framework with a chlorophenyl group and nitro substitution. Its reported molecular formula is C17H12ClN5O2, with a molecular weight of approximately 353.77 g/mol. Its IUPAC designation is 6-(2-chlorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine.
As a benzodiazepine derivative, clonazolam is associated with central nervous system depressant effects. Reported effects can include sedation, impaired coordination, reduced alertness, memory impairment, and amnesia. The compound has also been associated with prolonged periods of unconsciousness and other serious adverse effects.
The high potency reported for clonazolam makes its effects particularly difficult to predict. Individual responses can vary, and combining benzodiazepine-type compounds with alcohol, opioids, or other central nervous system depressants can substantially increase the risk of severe sedation and respiratory depression.
Clonazolam 0.5mg is not an approved therapeutic medicine, and its safety profile has not been established to the same degree as prescription benzodiazepines. Information concerning the compound should therefore be interpreted within an appropriate scientific, toxicological, and regulatory context.
Clonazolam 0.5mg is a synthetic benzodiazepine derivative also known as clonitrazolam. It belongs to the triazolobenzodiazepine family and is structurally related to other compounds within the benzodiazepine class.
Clonazolam was originally synthesized in the 1970s but was never developed as an approved pharmaceutical medicine. It later became associated with the market for novel psychoactive substances. Compared with established benzodiazepines, substantially less clinical information is available concerning its pharmacology, metabolism, toxicity, and long-term effects.
The chemical structure of Clonazolam 0.5mg includes a triazolobenzodiazepine framework with a chlorophenyl group and nitro substitution. Its reported molecular formula is C17H12ClN5O2, with a molecular weight of approximately 353.77 g/mol. Its IUPAC designation is 6-(2-chlorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine.
As a benzodiazepine derivative, clonazolam is associated with central nervous system depressant effects. Reported effects can include sedation, impaired coordination, reduced alertness, memory impairment, and amnesia. The compound has also been associated with prolonged periods of unconsciousness and other serious adverse effects.
The high potency reported for clonazolam makes its effects particularly difficult to predict. Individual responses can vary, and combining benzodiazepine-type compounds with alcohol, opioids, or other central nervous system depressants can substantially increase the risk of severe sedation and respiratory depression.
Clonazolam 0.5mg is not an approved therapeutic medicine, and its safety profile has not been established to the same degree as prescription benzodiazepines. Information concerning the compound should therefore be interpreted within an appropriate scientific, toxicological, and regulatory context.
